Mice genetically engineered to lack the amino acid cysteine, and fed a cysteine-free diet, lost 30 percent of their body weight in a week.

Updated results of fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): a ...

ReproNovo has licensed rights to two drugs from Mereo BioPharma and ObsEva that it thinks could address fertility issues in ...

A study led by a physician-scientist at the University of Arizona College of Medicine–Tucson's Sarver Heart Center identified ...

Learn about real user results, key benefits, and possible side effects. Discover whether this is worth trying.

Bone is not the inert structure we often imagine. It's alive, adapting daily to load-bearing and impact. But with over 200 ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” ...

Discover 9 promising small molecule drug discovery companies that recently raised funding for their potentially breakthrough ...

BioMarin has followed through on its shift to external innovation, inking a deal to buy Inozyme for $270 million to add a ...

Aptamer Group plc, the leading developer of next-generation synthetic binders delivering innovation to the life science ...

Aptamer Group plc has announced two new development contracts for its Optimer binders and a licensing heads of terms ...